Harbour BioMed & AstraZeneca Partner to Develop Multi-Specific Antibodies across Various Therapeutic Areas
Shots:
- Harbour & AstraZeneca (AZ) have entered into a global strategic collaboration to identify & develop novel msAbs for various therapeutic areas, using Harbour’s Mice Ab platform
- As per the deal, Harbour will get $175M in upfront, near-term milestones, & option fees, along with ~$4.4B in development & commercial milestones, plus tiered royalties on net sales, with a $105M investment, allowing AZ to acquire a 9.15% stake. Harbour will establish a Beijing R&D center to support joint efforts
- AZ will have the option to license 2 preclinical immunology programs & nominate targets for Harbour, with the potential to incl. more programs over 5yrs.; alliance can extend for another 5yrs. by common accord
Ref: Harbour BioMed | Image: Harbour & AstraZeneca
Related News:- Harbour BioMed Enters into a Collaboration with Insilico Medicine to Advance AI-Driven Antibody Discovery and Development
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
